20201019 TG4001+avelumab SITC – EN
Category: TG4001
Transgene Reports Results from Clinical Study of TG4001 in Combination with Avelumab in Advanced HPV-Positive Cancers
CP TG4001+avelumab EN – Vdef-
Transgene Reports First Promising Efficacy Results with TG4001 in Combination with Avelumab in HPV-Positive Cancer at ESMO 2019
20190930 PR TG4001 ESMO EN
Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic HPV16 positive cancers
Christophe Le Tourneau et al. ESMO 2019 Download the poster here Poster Presentation
Peer-reviewed publications confirm the potential of Transgene’s TG4001 and TG6002
20190605 Transgene publi TG4001 TG6002 EN
The efficacy and safety of Tipapkinogen Sovacivec (TG4001) therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up
Diane M. Harper, et al. Gynecologic Oncology, April 2019 – Download the article The publication has been featured in The Lancet Oncology and Medpage Today Publication
Transgene Completes Safety and Tolerability Assessment of TG4001 in Combination with Avelumab in Phase 1b Part of Trial in HPV-Positive Cancer Patients
20181220-Phase-1-TG4001-EN
First Patient Treated in a Phase 1b/2 Trial of TG4001 in Combination with Avelumab in HPV-Positive Cancers
170919-Transgene-FPI-Announcement_US
Transgene Announces Collaboration with Merck and Pfizer to Evaluate the Combination of TG4001 with Avelumab in HPV-Positive Head & Neck Cancer in a Phase 1/2 Study
alliance_transgene-collab-press-release_row
Immunological characterization of a modified vaccinia virus Ankara vector expressing the human papillomavirus 16 E1 protein.
Christelle Remy-Ziller, et al. Clinical and vaccine immunology. 2014; 21(2): 147-155 – Download the article Publication
